Skip to main content
Premium Trial:

Request an Annual Quote

Mike Hunkapiller, Sue Siegel, Jonathan Rothberg, Bill Ericson, David Weitz, Jeff Samberg, Thomas Meyers, Maynard Olson, Katherine Flagg

Mike Hunkapiller and Sue Siegel recently joined the board of directors of RainDance Technologies (see feature in this issue).
Hunkapiller is a general partner at Alloy Ventures, which he joined in 2004 after 21 years at Applied Biosystems, where his last position was president and general manager. He holds a BS in chemistry from Oklahoma Baptist University and a PhD in chemical biology from Caltech. Hunkapiller is also on the board of Pacific Biosciences, which is developing a next-generation DNA sequencer and is backed by Alloy Ventures.
Siegel is a partner with Mohr Davidow Ventures, which participated in a $23.7 million round of financing RainDance raised earlier this year (see In Sequence 05-08-07). Prior to joining MDV, she was president and director of Affymetrix. Siegel is also a member of the board of directors of Pacific Biosciences, which is also backed by MDV.
RainDance’s other directors are Jonathan Rothberg, a company founder, who also founded 454 Life Sciences; Bill Ericson, who leads investments in life sciences and software for MDV; and David Weitz, a professor of applied physics and physics at Harvard University. Jeff Samberg, managing member of Acadia Woods Partners, a New York-based investment partnership, is a board observer.

Thomas Meyers has joined the new Boston Office of Cooley Godward Kronish, a law firm specializing in representing technology and life sciences companies. He was chair of the intellectual property department at Sullivan & Worcester’s Boston office and recently was general counsel of Helicos BioSciences.

Maynard Olson will receive the 2007 Gruber Prize for Genetics on Oct. 24 at the American Society of Human Genetics annual meeting in San Diego, California. He is a professor of Genome Sciences at the University of Washington. The prize consists of a gold medal and $500,000. Olson was a key player in the Human Genome Project.

Katherine Flagg has become vice president of sales for ForteBio, a developer of label-free systems for real-time detection and analysis of molecular interactions. She joined the company from Rapid Micro Biosystems, where she was vice president for business development. Previously, she represented automated DNA sequencing and synthesis products at Pharmacia Biotech, now GE Healthcare. Flagg holds a BS in nutrition from Douglass College at Rutgers University.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.